
    
      Patients: early ( less than 6 months), active ( DAS>5.2),potentially severe ( Leiden score>6)
      Study design:12 months, prospective , randomized, open Study treatments: Methotrexate at a
      weekly dose of 0.3mg/kilo alone or in combination with adalimumab 40 mg every the other week
      Outcome measures: DAS over the 12 months
    
  